BRPI0418764A - uso de espinosina ou um derivado ou sal da mesma fisiologicamente aceitável - Google Patents

uso de espinosina ou um derivado ou sal da mesma fisiologicamente aceitável

Info

Publication number
BRPI0418764A
BRPI0418764A BRPI0418764-4A BRPI0418764A BRPI0418764A BR PI0418764 A BRPI0418764 A BR PI0418764A BR PI0418764 A BRPI0418764 A BR PI0418764A BR PI0418764 A BRPI0418764 A BR PI0418764A
Authority
BR
Brazil
Prior art keywords
spinosine
salt
physiologically acceptable
acceptable derivative
derivative
Prior art date
Application number
BRPI0418764-4A
Other languages
English (en)
Inventor
Kristina Clare Hacket
Lionel Barry Lowe
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0418764A publication Critical patent/BRPI0418764A/pt
Publication of BRPI0418764B1 publication Critical patent/BRPI0418764B1/pt
Publication of BRPI0418764B8 publication Critical patent/BRPI0418764B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"USO DE ESPINOSINA OU UM DERIVADO OU SAL DA MESMA FISIOLOGICAMENTE ACEITáVEL" Uma espinosina ou um derivado ou sal deste fisiologicamente aceitável para promover ou acelerar a cura de ferimento em seres humanos.
BRPI0418764A 2004-04-29 2004-04-29 uso de espinosina, ou de um derivado ou sal fisiologicamente aceitável da mesma, na preparação de medicamentos para promover ou acelerar a cura de ferimento em um ser humano BRPI0418764B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/011268 WO2005112950A1 (en) 2004-04-29 2004-04-29 Spinosyns for wound healing

Publications (3)

Publication Number Publication Date
BRPI0418764A true BRPI0418764A (pt) 2007-07-24
BRPI0418764B1 BRPI0418764B1 (pt) 2019-01-22
BRPI0418764B8 BRPI0418764B8 (pt) 2021-07-27

Family

ID=34957480

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418764A BRPI0418764B8 (pt) 2004-04-29 2004-04-29 uso de espinosina, ou de um derivado ou sal fisiologicamente aceitável da mesma, na preparação de medicamentos para promover ou acelerar a cura de ferimento em um ser humano

Country Status (21)

Country Link
US (2) US7709447B2 (pt)
EP (1) EP1744763B1 (pt)
JP (1) JP4880589B2 (pt)
CN (1) CN1942194B (pt)
AT (1) ATE454156T1 (pt)
AU (1) AU2004319804B2 (pt)
BR (1) BRPI0418764B8 (pt)
CA (1) CA2563800C (pt)
CY (1) CY1109840T1 (pt)
DE (1) DE602004025050D1 (pt)
DK (1) DK1744763T3 (pt)
EA (1) EA010975B1 (pt)
ES (1) ES2336573T3 (pt)
HR (1) HRP20100137T1 (pt)
IL (1) IL178399A (pt)
MX (1) MXPA06012388A (pt)
NO (1) NO337210B1 (pt)
PL (1) PL1744763T3 (pt)
PT (1) PT1744763E (pt)
SI (1) SI1744763T1 (pt)
WO (1) WO2005112950A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0603252D0 (en) 2006-02-17 2006-03-29 Axcess Ltd Dissolution aids for oral peptide delivery
US8791153B2 (en) 2006-10-12 2014-07-29 Sanofi-Topaz, Inc. Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment-resistant strains of head lice
CA2764526A1 (en) 2009-06-24 2010-12-29 Christine Kritikou The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer
US9918991B2 (en) * 2010-01-14 2018-03-20 Hydromer, Inc. Topical antimicrobial compositions and methods of using same
US9474729B2 (en) * 2010-01-14 2016-10-25 Hydromer, Inc. Topical antimicrobial compositions and methods of using same
EP2528587B1 (en) 2010-01-25 2015-03-18 Eli Lilly and Company Spinosyns for use in internally controlling or treating equine bot larvae
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
EP2654757A1 (en) 2010-12-22 2013-10-30 Entarco SA The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents
EP3344612B1 (en) 2015-09-03 2020-06-17 Agrimetis, LLC Spinosyn derivatives as insecticides
MX376448B (es) 2017-01-13 2025-03-07 Agrimetis Llc Derivados de espinosina aziridina y métodos de preparación.
CN112770742A (zh) 2018-07-27 2021-05-07 阿佩塔生物科学有限公司 用于治疗蠕形螨引起的眼部和面部疾病的多杀菌素制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE324039T1 (de) 1999-08-12 2006-05-15 Lilly Co Eli Verwendung von spinosad oder einer zusammensetzung enthaltend spinosad
WO2001011961A1 (en) 1999-08-12 2001-02-22 Eli Lilly And Company Control of ectoparasites using spinosyns
US6727228B2 (en) * 2001-04-25 2004-04-27 Johnson & Johnson Consumer Companies, Inc. Pediculicidal and ovacidal treatment compositions and methods for killing head lice and their eggs
US20030026848A1 (en) * 2001-07-06 2003-02-06 Joshi Ashok V. Beneficial materials for topical or internal use by a human or other animal
IL160619A0 (en) * 2001-09-17 2004-07-25 Lilly Co Eli Pesticidal formulations pesticidal formulations

Also Published As

Publication number Publication date
IL178399A0 (en) 2008-04-13
JP4880589B2 (ja) 2012-02-22
CA2563800A1 (en) 2005-12-01
EP1744763A1 (en) 2007-01-24
MXPA06012388A (es) 2007-01-17
IL178399A (en) 2011-03-31
DK1744763T3 (da) 2010-03-22
ATE454156T1 (de) 2010-01-15
EP1744763B1 (en) 2010-01-06
US8536142B2 (en) 2013-09-17
EA200602002A1 (ru) 2007-02-27
ES2336573T3 (es) 2010-04-14
PT1744763E (pt) 2010-03-31
CY1109840T1 (el) 2014-09-10
PL1744763T3 (pl) 2010-06-30
CN1942194A (zh) 2007-04-04
CA2563800C (en) 2011-06-28
SI1744763T1 (sl) 2010-05-31
DE602004025050D1 (de) 2010-02-25
BRPI0418764B8 (pt) 2021-07-27
HRP20100137T1 (hr) 2010-04-30
EA010975B1 (ru) 2008-12-30
AU2004319804B2 (en) 2010-08-05
US7709447B2 (en) 2010-05-04
HK1099519A1 (en) 2007-08-17
CN1942194B (zh) 2010-05-26
US20100173857A1 (en) 2010-07-08
JP2007534750A (ja) 2007-11-29
US20070167379A1 (en) 2007-07-19
NO337210B1 (no) 2016-02-08
WO2005112950A1 (en) 2005-12-01
NO20065447L (no) 2006-11-27
AU2004319804A1 (en) 2005-12-01
BRPI0418764B1 (pt) 2019-01-22

Similar Documents

Publication Publication Date Title
BRPI0519195A2 (pt) composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
ATE486860T1 (de) Phenothiazin-derivat zur wundheilung
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
BRPI0519391B1 (pt) composição e uso da mesma para promover a saúde oral em um animal de companhia e kit para administração da composição
PA8570901A1 (es) Derivados de acil-4-carboxifenilurea, procedimientos para su preparacion y su uso
BRPI0416796A (pt) compostos orgánicos
BRPI0615157A2 (pt) composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
PA8657201A1 (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4, 5-d] pirimidin-2-ona 3, 5-disustituida y 3, 5, 7 - trisustituida y profarmacos de los mismos
ECSP066313A (es) Derivados de la piridazina y su uso como agentes terapéuticos
ECSP066315A (es) Derivados de la piridazina y su uso como agentes terapéuticos
BRPI0912411A2 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro.
BR0311931A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença ou condição mediada com hppar em um paciente
HN1999000183A (es) Preparado farmaceuticos de moxifloxacina
ECSP066734A (es) Derivados de ácido 7-fenilamino-4-quinolona-3-carboxílico, métodos para su producción y su uso como medicamentos
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
HN2008001666A (es) Derivados acidos de cicloalquilamino
HN2003000185A (es) Difenilazetidinonas sustituidas en grupo acido, procedimiemto para su preparacion, medicamentos que comprenden estso compuestos y su uso.
BRPI0418764A (pt) uso de espinosina ou um derivado ou sal da mesma fisiologicamente aceitável
GT200500378A (es) Macrolidos
BRPI0510449A (pt) uso de formulações de meloxicam em medicina veterinária
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
ATE347358T1 (de) Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
BRPI0409681A (pt) derivados de wortmanina solúveis em água
PT1220676E (pt) Prevencao do cancro colorrectal

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE. PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2260 DE 29/04/2014.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: ELANCO US INC. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/04/2004, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2825 DE 25-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.